Rebecca Hedgecott (a previous intern at Procarta) is to skydive to raise money for Cystic fibrosis reaearch on the 18th. April.
Dr Michael McArthur (CSO) will give a presentation entitled ‘Pre-clinical update on a novel class of oligonucleotide antibacterials’ at the Eurotides conference to be held in Berlin to be held on 15 – 16 Nov, 2011.
Procarta has been invited to present a pitch in this years prestigious ‘Biotrinity iInvestment Conference’ to be held at Newbury Racecourse (UK), 12-14 April 2011.
Following Procarta’s success in raising fresh capital in a round led by Morningside Group Dr David Knowles has been invited to take the Chairmanship of the company.
Procarta Biosystems Ltd., which is developing a novel class of DNA-based antibiotics capable of tackling drug-resistant infections, announced today a round of equity investment totaling £730,000 with the potential to rise to £1.25 million.
Dr Michael McArthur has been named the winner of ‘Most Promising Innovator of the Year’ award at BBSRC’s Innovator of the Year event for his work using novel antibacterials to combat drug-resistant bacterial infections.